Toho : Notice Regarding Marketing Approvals for 1 Ingredient / 1 Product of Generic Drugs for KYOSOMIRAI PHARMA(147 KB)
August 15, 2021
Share
August 16, 2021
To whom it may concern:
Company Name
TOHO HOLDINGS CO., LTD.
Corporate
Atsushi Udoh, President and
Representative
Representative Director
(First Section of Tokyo Stock Exchange
Securities Code:8129)
Contact:
Makoto Kawamura, Director and General
Manager, Corporate Management
Division and Corporate Planning and
Investor Relations Department
(TEL: 81-3-6838-2803)
Notice Regarding Marketing Approvals for
1 Ingredient / 1 Product of Generic Drugs for KYOSOMIRAI PHARMA
TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received approvals for marketing of 1 ingredient / 1 product of generic drugs today on August 16, 2021 as below.
Product list approved for marketing
Class
Product Name
Original Brand Name
Endothelin receptor antagonist
Ambrisentan Tablets 2.5mg
Volibris®Tablets
"KMP"
2.5mg
Attachments
Original document
Permalink
Disclaimer
Toho Holdings Co. Ltd. published this content on 16 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 September 2021 09:01:01 UTC.
Toho Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical wholesale business. The Company operates through five business segments. The Pharmaceutical Wholesale segment purchases pharmaceuticals and medical-related products from pharmaceutical manufacturers and sells them to hospitals, clinics and dispensing pharmacies. It is also engaged in the provision of data processing system and rental of real estate. The Dispensing Pharmacy segment is engaged in the management of insurance dispensing pharmacies and dispensing pharmacies. The Pharmaceutical Manufacture and Sale segment is engaged in the manufacture and sale of generic drugs and contract manufacturing of injectable drugs. The Clinical Trial Facility Support segment is engaged in the provision of support for clinical trial facilities. The Information Equipment Sales segment is engaged in the planning and sale of information processing equipment.
TOHO HOLDINGS CO., LTD. 
